ClinicalTrials.gg
CompletedNCT01578330Updated Jun 7, 2016Results posted

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

A Phase 4 interventional study of Fingolimod in Multiple Sclerosis and Relapsing-Remitting, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-06-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
28th of 34
42 · median 167
Started
2012
with 3 others
Phase 4
17 of 34
none open now
Registered
20th of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 28th largest by enrollment, is one of 4 that started in 2012, is one of 17 in phase 4, and was the 20th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.

03

Conditions studied

  • Multiple Sclerosis
  • Relapsing-Remitting

Keywords

  • Relapsing remitting multiple sclerosis
  • Fingolimod
  • FTY720
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with RRMS as described in 2005 Mc Donald criteria
  2. Provided written prior to any intervention
  3. Female or male patients aged 18-65 years
  4. Unresponsive to treatment with a beta interferon or glatiramer acetate for a minimum of one year at and at adequate dose and with high disease activity

    (Unresponsive patients: patients with no changes in relapses, increased relapses, severer relapses with one-year treatment or those who had had at least one relapse during the past one year under previous treatments and one or multiple contrast enhancing lesions in cranial MRI or increased T2 lesions in successive MRIs)

  5. EDSS score below 5.5 at baseline

Exclusion criteria

Exclusion Criteria:

  • Treatment-naive RRMS patients 2. History of a chronic disease of the immune system other than MS or known immunodeficiency 3. Past or current 4. Diabetic patients with mild or severe, non-proliferative or proliferative diabetic retinopathy and uncontrolled diabetic patients with > 8% 5. Evidence of macular edema (patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at screening.) 6. Evidence of uveitis 7. EDSS score > 5.5 at baseline 8. Active systemic bacterial, viral or fungal infections, or known to have AIDS, , infection or have positive antibody, Hepatitis B surface antigen or Hepatitis C antibody tests 9. No history of varicella and negative varicella-zoster virus IhH antibody test at screening (such patients may be included after being administered VZV vaccine, at least 1 month following vaccination.) 10. Patients who received any live or during the last one month (including varicella-zoster virus or measles) 11. Patients who received total lymphoid irradiation or bone marrow transplantation 12. Patient who received any of the treatment below:

    1. or adrenocorticotropic hormone (ACTH) during the last 1 month
    2. medications such as azathioprine or methotrexate etc.
    3. Immunoglobulin treatment during the last 3 months
    4. Cladribine, cyclophosphamide, mitoxantrone, natalizumab at any time 13. Patients with any of the following cardiovascular conditions: Resting heart rate \< 45 bpm/min Cardiac failure at time of screening (Class III according to classification) or any severe cardiac as determined by the physician Myocardial infarction during the last 6 months History of Mobitz Type II grade 2 AV block Past or current grade 3 AV block Confirmed history of sick sinus syndrome or sino-atrial heart block arrhythmia requiring current treatment with Class Ia drugs (ajmaline, disopyramid, procainamide, quinidine) hypertension uncontrolled with medication 14. Patients with any of the pulmonary conditions below severe respiratory disease or pulmonary fibrosis Uncontrolled asthma 15. Pregnant or nursing (lactating) women (pregnancy is defined as the state of a female after conception and until the termination of gestation and should be confirmed by a positive hCG laboratory test (> 5 mIU/ml).

      1. Patients with any of the hepatic conditions below: Alcohol abuse, chronic hepatic or biliary disease, severe hepatic impairment (Child- Pugh class C) Total above the provided that it is not associated with Gilbert's syndrome Conjugated bilirubin above the upper limit of normal Alkaline phosphate (AP) 1.5 times above the upper limit of normal (SGOT), ALT (SGPT) 2 times above the upper limit of normal, gamma-glutamyl-transferase (GGT) 3 times above the upper limit of normal
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Fingolimod, FTY720

    Patients received fingolimod 0.5 mg oral capsules daily with or without food.

    Drug: Fingolimod

Interventions

  • Fingolimod 0.5mg orally once a day without food.

06

What researchers measure

Primary outcomes

  1. Mean Patient-Reported Treatment Satisfaction Questionnaire for Medication Scores (TSQM-9)

    The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

    Time frame: Baseline and month 12

Secondary outcomes

  1. Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).

    The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

    Time frame: Month 1

  2. Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).

    The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

    Time frame: Month 6

  3. Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).

    The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

    Time frame: Month 12

07

Results

Posted Jun 7, 2016

Participant flow

Participant flow — Overall Study
MilestoneFingolimod, FTY720
Started42
Per protocol population35
Completed35
Not completed7
Withdrew: Adverse event2
Withdrew: Protocol violation5

Outcome measures

PrimaryMean Patient-Reported Treatment Satisfaction Questionnaire for Medication Scores (TSQM-9)

The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

Time frame:
Baseline and month 12
Reported as:
Mean · Scores on a scale
Mean Patient-Reported Treatment Satisfaction Questionnaire for Medication Scores (TSQM-9)
Scores on a scaleFingolimod, FTY720
Baseline (n=34)32.0 ± 9.9
Month 12 (n=32)44.7 ± 9.9
SecondaryMean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).

The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

Time frame:
Month 1
Reported as:
Mean · score on scale
Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).
score on scaleFingolimod, FTY720
Physical Function59.7 ± 30.9
Physical Role53.6 ± 43.8
Pain61.7 ± 23.7
General Health47.8 ± 20.5
Vitality28.9 ± 23.1
Social Function61.8 ± 26.4
Emotional Role48.4 ± 43.0
Mental Health31.5 ± 17.0
SecondaryMean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).

The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

Time frame:
Month 6
Reported as:
Mean · score on scale
Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).
score on scaleFingolimod, FTY720
Physical Function (n=33)57.9 ± 31.1
Physical Role (n=34)47.8 ± 46.0
Pain (n=34)62.6 ± 24.8
General Health (n=33)48.5 ± 20.3
Vitality (n=34)35.2 ± 22.9
Social Function (n=34)60.6 ± 29.9
Emotional Role (n=34)54.8 ± 43.3
Mental Health (n=34)36.5 ± 20.3
SecondaryMean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).

The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.

Time frame:
Month 12
Reported as:
Mean · score on scale
Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).
score on scaleFingolimod, FTY720
Physical Function (n=31)59.5 ± 34.3
Physical Role (n=32)46.9 ± 44.7
Pain (n=32)65.9 ± 23.3
General Health (n=31)50.8 ± 21.9
Vitality (n=32)33.1 ± 20.0
Social Function (n=32)65.8 ± 29.1
Emotional Role (n=31)52.7 ± 46.2
Mental Health (n=32)36.3 ± 20.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod, FTY720—4/42 (9.5%)24/42 (57.1%)
Most frequent serious events
Most frequent serious events
EventFingolimod, FTY720
Multiple Sclerosis aggravatedImmune system disorders1/42
FractureInjury, poisoning and procedural complications1/42
Medication taken before pregnancyInjury, poisoning and procedural complications1/42
Middle ear infection surgerySurgical and medical procedures1/42
Most frequent other events
Most frequent other events
EventFingolimod, FTY720
Urinary infectionRenal and urinary disorders9/42
Upper respiratory infectionRespiratory, thoracic and mediastinal disorders8/42
LymphopeniaBlood and lymphatic system disorders7/42
Increase of hepatic enzymesHepatobiliary disorders5/42
Multiple Sclerosis AggravatedImmune system disorders4/42
HeadacheNervous system disorders4/42
HyperlipidemiaMetabolism and nutrition disorders4/42
Tooth abscessInfections and infestations3/42
NauseaGastrointestinal disorders3/42
IncontinenceRenal and urinary disorders3/42

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fingolimod, FTY720
Mean35.7 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod, FTY720
Female16
Male26
08

Study locations

11 sites
  • Novartis Investigative Site
    Altunizade, 34662, Turkey
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06500, Turkey
  • Novartis Investigative Site
    Atakum / Samsun, 55139, Turkey
  • Novartis Investigative Site
    Bursa, 16059, Turkey
  • Novartis Investigative Site
    Fatih / Istanbul, 34098, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
  • Novartis Investigative Site
    Mecidiyekoy/Istanbul, 34394, Turkey
  • Novartis Investigative Site
    Trabzon, 61080, Turkey
  • Novartis Investigative Site
    Uskudar / Istanbul, 34668, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2012
First posted
Apr 16, 2012
Start
Oct 2012
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jun 7, 2016
Last update
Jun 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01578330
Responsible party
Sponsor
First posted
Apr 16, 2012
Start date
Oct 2012
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jun 7, 2016
Last update
Jun 7, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion